

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following observations was reported in the Phase III KEYNOTE-355 study evaluating pembrolizumab with chemotherapy versus placebo with chemotherapy for patients with metastatic triple-negative breast cancer (TNBC)?**
 - a. Overall survival (OS) and progression-free survival (PFS) were not significantly improved with the addition of pembrolizumab to chemotherapy
 - b. PFS but not OS was significantly improved with the addition of pembrolizumab to chemotherapy
 - c. PFS and OS were significantly improved with the addition of pembrolizumab to chemotherapy**
- 2. In the DESTINY-Breast04 study evaluating trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-low metastatic breast cancer treated with 1 to 2 lines of chemotherapy in the metastatic setting, what was observed in patients with HR-negative disease?**
 - a. OS and PFS were not significantly improved with T-DXd
 - b. PFS but not OS was significantly improved with T-DXd
 - c. PFS and OS were significantly improved with T-DXd**
- 3. The ongoing Phase III DESTINY-Breast06 trial is investigating T-DXd versus investigator's choice of chemotherapy for which patients with breast cancer?**
 - a. Those with newly diagnosed HER2-positive advanced disease
 - b. Those with chemotherapy-naïve HER2-positive advanced disease
 - c. Those with chemotherapy-naïve HER2-low advanced disease
 - d. Those with chemotherapy-naïve HER2-ultralow advanced disease**
 - e. Those with chemotherapy-refractory HER2-low advanced disease
 - f. Those with chemotherapy-refractory HER2-ultralow advanced disease
- 4. Which of the following proteins is targeted by datopotamab deruxtecan?**
 - a. CDH1
 - b. CHEK2
 - c. PALB2
 - d. TROP2**
- 5. The ongoing Phase III ASCENT-07 study is evaluating sacituzumab govitecan versus treatment of physician's choice in which of the following settings?**
 - a. As first-line therapy for ER-negative, HER2-positive metastatic breast cancer (mBC)
 - b. As first-line therapy for ER-positive, HER2-negative mBC**
 - c. As second-line therapy for ER-negative, HER2-positive mBC
 - d. As second-line therapy for ER-positive, HER2-negative mBC